Heart failure therapy by GLP-1RAs Although a meta-analysis of large-scale clinical trials suggested that GLP-1RAs reduce heart failure hospitalizations (HHF) by approximately 10% in patients with diabetes at high cardiovascular risk [22, 23], the treatment effects on the risk of HHF in individual trials other than AMPLITUDE-O were not significant (Tables 1, 2)
Thus, sulforaphane gained traction as a safer NRF2 activator, outpacing tBHQ in research focused on neuroprotection
Listen to the patient, don't dismiss them, but be honest
doi: 10.1111/j.1469-8137.2011.03889.x 3 BendahmaneA.KanyukaK.BaulcombeD
The peptide also appears to have antioxidant properties through upregulation of endogenous antioxidant enzyme systems including superoxide dismutase, catalase, and glutathione-related enzymes
These symptoms are nonspecific and require clinical evaluation